ARCHIVES

First-Line Bendamustine Doubles PFS In Non-Hodgkin and Mantle Cell Lymphoma

This article is from The Cancer Letter archive.

Vol. 36 No. 2 | February 22, 2013

Download PDF Visit The Full Archive

Related Articles

Don’t Blame FDA For All Problems, Broder Says

September 7, 1990

Believers “Flout Fundamental Law Of Physics,” Park Says.

August 1, 2008

NCI Prepares To Dispense A Torrent Of New Money For Cancer Research.

March 6, 2009

Velcade Addition Can Improve Graft-Versus-Host Outcomes

December 27, 2013

SWOG Wins NCI Grant Renewal For Six Years

April 16, 2010

FDA Advisors Recommend Approval Of Topotecan for Ovarian Cancer

April 26, 1996